year-old) showing a better response at two years than older patients.
To describe the clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) who developed pneumatosis intestinalis (PI).
This case series was conducted in intensive care units at two large tertiary care centers within the Northwell Health System, located in New York State. Patients were included if they were identified as having confirmed COVID-19 as well as pneumatosis intestinalis from March 16, 2020 to July 31, 2020. Bromoenol lactone order Patient demographics, clinical characteristics, vasopressor use, anticoagulation use, opiate use, paralytic use, COVID-19 treatment regimen, serum lactate, arterial pH, serum bicarbonate, subsequent intervention, and outcomes during hospitalization were collected. Results A total of nine patients were identified. Average serum lactate was 4.33 mmol/L at time of diagnosis. Portal venous gas (56%) and bowel dilation (56%) were common radiographic findings. Subsequent morbidity (increased vasopressor requirements - 67%, acute kidney injury - 67%, increased oxygen requirements - 44%) and mortality (78%) were high. PI occurred despite a majority of patients being on anticoagulation (78%). Interleukin-6 (IL-6) inhibitors were commonly administered (56%) prior to development of PI.
Pneumatosis intestinalis in COVID-19 is clinically significant, with high morbidity and mortality, and is also likely underdiagnosed.
Pneumatosis intestinalis in COVID-19 is clinically significant, with high morbidity and mortality, and is also likely underdiagnosed.Parotid glands, which are predominantly composed of serous acini, are the largest salivary glands in the human body. Mucoepidermoid carcinoma (MEC) of the parotid gland is the most common parotid tumour that routinely presents as a painless, fixed mass below the ears. However, its presentation as a fungating mass remains exceedingly rare. Due to the intimate anatomical relationship between the parotid gland and the facial nerve, parotid malignancies can culminate in facial nerve palsy, posing an onerous surgical challenge. In this paper, we chronicle the case of a male who presented with a fungating/exophytic mass and facial nerve weakness. A superficial parotidectomy was performed, and the eventual histopathological workup divulged an advanced mucoepidermoid parotid carcinoma entirely encasing the marginal mandibular nerve. Consequently, the marginal mandibular nerve was sacrificed, alluding to the remarkable surgical challenge encountered. Clinically, this manifested as an impairment of the motor function in the patient's left lower lip.
The use of modern radiotherapy techniques (MRTs)hascontributed to reducedtreatment-related toxicities through better avoidance of normal structures and dose tapering, and hasenabled the delivery of higher doses continuously. The purpose of this study was to review retrospectively (1) outcomes for anal cancer treated at BC Cancer (Canada) using MRT, and (2) the utilization and effect of dose escalation on cancer-related outcomes.
Patients between 2010 and 2016 with biopsy-proven anal cancer, aged >18 years, and treated with primary curative-intent chemoradiation using intensity modulatedradiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) were included. Primary end points included overall survival (OS), relapse-free survival (RFS), and colostomy-free survival (CFS). Kaplan-Meier curves were created for prognostic factors, as well as dose escalation (>54 Gy vs. ≤54 Gy). Univariate and multivariate analyses were performed to evaluate predictors of the outcome.
A total of 273 patients were anfrequently prescribed, appeared tolerable, but more often required a break. Prospective trials are needed to clarify efficacy of such regimens.
BC Cancer outcomes for anal cancer treated with MRTs are comparable to what has been previously reported. Unplanned breaks were notably few, and short. Treatment-related colostomies were rare. Dose-escalated regimens were infrequently prescribed, appeared tolerable, but more often required a break. Prospective trials are needed to clarify efficacy of such regimens.Introduction A proportionate short stature (SS) assessment involves the documentation of normal growth hormone secretion via a growth hormone (GH) stimulation test. All available GH stimulation tests have some disadvantages. The decision to initiate GH therapy is dependent on multiple factors, including the GH stimulation test result. However, many patients receive GH therapy, even if they have a normal GH stimulation test result, with the indication of a presumed idiopathic SS. Objective In this study, we investigated the use of the GH stimulation test result in initiating GH therapy. Method A cross-sectional study was conducted with patients diagnosed with proportionate SS. Age, gender, insulin-like growth factor 1 (IGF-1) level, and GH stimulation test results were collected retrospectively from the electronic medical records. The main outcome variable was the decision related to prescribing GH therapy. Results A total of 286 patient charts were reviewed, and the majority (n = 201, 64.6%) were male. For just less than half (n = 136, 47.6%), the result of the GH stimulation test was ≥ 10 ng/mL, in a small proportion (n = 53, 18.5%) the result was less then 5 ng/mL, and for the rest of the cohort, the result was 5.0 - 9.9 ng/mL. The majority (n = 219, 70.4%) received GH therapy, irrespective of the GH stimulation test result. The odds ratio (OR) for GH treatment was 3.9 (CI 1.79 - 8.49) and 3.0 (CI 1.21 - 7.42) for patients with a result less then 5 ng/mL and 5.0 - 9.9 ng/mL, respectively, compared to the group with a result of ≥ 10 ng/mL. Conclusion GH therapy is frequently prescribed for patients with SS, irrespective of the GH stimulation test result. However, the group with SS with a result of less then 9.9 ng/mL was more likely to receive GH therapy. The question of whether a GH stimulation test is required, in the context of SS, is debatable.Background Challenges in the diagnosis of obstructive jaundice include locating the level of obstruction, knowing the cause of obstruction, and differentiating between benign and malignant causes. Imaging plays a significant role in detecting the causes of obstruction. Radiologists aim to diagnose biliary obstruction, its level, extent, and probable causes to determine the appropriate treatment for each case. Methods Our study is a retrospective medical record review study. It included 150 patients who had ultrasound (US) diagnosis of biliary obstruction and underwent magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP) in King Fahad Specialist Hospital, Buraidah. The patients' medical records have been reviewed to measure the sensitivity and specificity of US, MRCP, and ERCP. Results Statistical analysis of the data showed that the sensitivity of US in detecting the most common cause of biliary obstruction, common bile duct (CBD) stone, was 26.6%, while the specificity was 100%.Bromoenol lactone order
Top comments (0)